SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
1 Online-Ressource.
Language
Englisch

Bibliographic citation
SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML ; volume:42 ; number:50 ; day:27 ; month:10 ; year:2023 ; pages:3670-3683 ; date:12.2023
Oncogene ; 42, Heft 50 (27.10.2023), 3670-3683, 12.2023

Creator
Mambro, Antonella Di
Arroyo-Berdugo, Yoana
Fioretti, Tiziana
Randles, Michael
Cozzuto, Luca
Rajeeve, Vinothini
Cevenini, Armando
Austin, Michael J.
Esposito, Gabriella
Ponomarenko, Julia
Lucas, Claire M.
Cutillas, Pedro
Gribben, John G.
Williams, Owen
Calle, Yolanda
Patel, Bela
Esposito, Maria Teresa
Contributor
SpringerLink (Online service)

DOI
10.1038/s41388-023-02840-1
URN
urn:nbn:de:101:1-2024022609503678282977
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 11:01 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Mambro, Antonella Di
  • Arroyo-Berdugo, Yoana
  • Fioretti, Tiziana
  • Randles, Michael
  • Cozzuto, Luca
  • Rajeeve, Vinothini
  • Cevenini, Armando
  • Austin, Michael J.
  • Esposito, Gabriella
  • Ponomarenko, Julia
  • Lucas, Claire M.
  • Cutillas, Pedro
  • Gribben, John G.
  • Williams, Owen
  • Calle, Yolanda
  • Patel, Bela
  • Esposito, Maria Teresa
  • SpringerLink (Online service)

Other Objects (12)

Molecular pathogenesis of disease progression in MLL-rearranged AML

Molecular pathogenesis of disease progression in MLL-rearranged AML

Reversal of MYB-dependent suppression of MAFB expression overrides leukaemia phenotype in MLL-rearranged AML

Reversal of MYB-dependent suppression of MAFB expression overrides leukaemia phenotype in MLL-rearranged AML

RNA binding proteins in MLL-rearranged leukemia

RNA binding proteins in MLL-rearranged leukemia

Using genome editing to model MLL rearranged leukemias

Hochschulschrift

Using genome editing to model MLL rearranged leukemias

NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia

NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia

Therapeutic strategies against hDOT1L as a potential drug target in MLL-rearranged leukemias

Therapeutic strategies against hDOT1L as a potential drug target in MLL-rearranged leukemias

The epigenetic regulators EP300/CREBBP represent promising therapeutic targets in MLL-rearranged acute myeloid leukemia

The epigenetic regulators EP300/CREBBP represent promising therapeutic targets in MLL-rearranged acute myeloid leukemia

The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency

The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency

Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia

Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia

FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia

FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia

Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias

Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias

Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia

Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia

Related objects